Alterity Therapeutics Limited (ASX:ATH)
0.0100
+0.0010 (11.11%)
Jul 4, 2025, 4:15 PM AEST
Alterity Therapeutics Employees
Alterity Therapeutics had 10 employees as of June 30, 2024. The number of employees decreased by 1 or -9.09% compared to the previous year.
Employees
10
Change (1Y)
-1
Growth (1Y)
-9.09%
Revenue / Employee
372.45K AUD
Profits / Employee
-1.98M AUD
Market Cap
91.27M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
CSL Limited | 32,698 |
Cochlear | 5,097 |
Sonic Healthcare | 42,000 |
Ramsay Health Care | 90,000 |
Telix Pharmaceuticals | 234 |
Ansell | 15,000 |
Regis Healthcare | 11,000 |
Mesoblast | 73 |
Alterity Therapeutics News
- 12 days ago - Alterity Therapeutics to Provide Corporate Update in Fireside Chat - GlobeNewsWire
- 7 weeks ago - Alterity Therapeutics Prominently Featured at the International MSA Congress - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy - GlobeNewsWire
- 2 months ago - Appendix 4C – Q3 FY25 Quarterly Cash Flow Report - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium - GlobeNewsWire
- 3 months ago - Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting - GlobeNewsWire
- 3 months ago - Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy - GlobeNewsWire